US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Sunshine Biopharma Inc. - Common stock (NQ:SBFM)

0.6665 -0.0211 (-3.07%)
Delayed Quote Updated: 3:59 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sunshine Biopharma Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
Via ACCESS Newswire
News headline image
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
Via ACCESS Newswire
News headline image
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
Via ACCESS Newswire
Sunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian Unit ↗
Via Stocktwits
News headline image
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
Via ACCESS Newswire
News headline image
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline
Via ACCESS Newswire
News headline image
Sunshine Biopharma Stock Is Surging Thursday: Here's What's Happening ↗
Shares of Sunshine Biopharma Inc. (NASDAQ: SBFM) are trading higher Thursday after the Florida-based pharmaceutical company announced the launch of a generic prescription drug. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin
Via ACCESS Newswire
News headline image
Sunshine Biopharma Stock is 34% Higher Since September as Investors Reward Performance Combined with Innovation (NASDAQ: SBFM)
Via AB Newswire
News headline image
Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)
Via ACCESS Newswire
News headline image
Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)
Via ACCESS Newswire
News headline image
Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience
Via ACCESS Newswire
News headline image
Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Sunshine Biopharma Stock Soars After Launch Of First Biosimilar In $10B Canadian Market: Retail Bulls Charge In ↗
The company launched Niopeg, a biosimilar to Neulasta, designed to reduce the risk of infection in chemotherapy patients. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market
Via ACCESS Newswire
News headline image
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’ ↗
CEO Steve Slilaty stated that the company is aiming to strengthen its presence in Canada’s generic drugs market, valued at $9.4 billion. 
Via Stocktwits
News headline image
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market
Via ACCESS Newswire
News headline image
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market
Via ACCESS Newswire
News headline image
Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug ↗
Its subsidiary launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market. 
Via Stocktwits
News headline image
The market is filled with gapping stocks in Monday's session. ↗
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
What's going on in today's pre-market session ↗
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >